TNF Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Intangible Assets (Tables)

Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2017

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Finite-Lived Intangible Assets

Intangible assets as of March 31, 2017 and December 31, 2016 and the movements for the periods then ended are as follows:

						Distributor &
		Patents &				Customer
		Trademarks				Relationships				Totals
*Cost or Deemed Cost*
At December 31, 2016		$	2,626,996			$	1,270,639			$	3,897,635
Additions			-				-				-
Disposals			-				-				-
At March 31, 2017		$	2,626,996			$	1,270,639			$	3,897,635

*Accumulated Amortization*
At December 31, 2016		$	1,325,221			$	1,270,639			$	2,595,860
Amortization Charge			42,777				-				42,777
Disposals			-				-				-
At March 31, 2017		$	1,367,998			$	1,270,639			$	2,638,637

*Net Book Value*
At December 31, 2016		$	1,301,775			$	-			$	1,301,775
At March 31, 2017		$	1,258,998			$	-			$	1,258,998

Schedule of Estimated Aggregate Amortization Expense of Fiscal Years

The estimated aggregate amortization expense for each of the five succeeding fiscal years is as follows:

Period				Amount
	2017			$	171,108
	2018			$	171,108
	2019			$	171,108
	2020			$	171,108
	2021			$	171,108